XML 42 R25.htm IDEA: XBRL DOCUMENT v3.21.2
Subsequent Events
 12 Months Ended
Sep. 30, 2021
Subsequent Events [Abstract]  
Subsequent Events
 
(17)
Subsequent Events
On October 25, 2021, the Company’s revolving credit facility with a commercial bank was amended primarily to: (i) increase the borrowing capacity to $200,000; (ii) extend the term to October 25, 2026; and (iii) modify the financial covenants to more closely align with the Company’s size and strategic plans. Other details of the credit facility remain relatively unchanged.
On November 9, 2021, notification was received from the FDA that emergency use authorization (“EUA”) had been granted for the Company’s Revogene SARS-CoV-2 assay.